Analysis reveals GGTLC1 as a prognostic biomarker in renal clear cell carcinoma, suggesting its role in improving patient outcomes.
Kidney renal clear cell carcinoma (KIRC), the most common type of renal cell carcinoma, is an immunobiologically and metabolically distinct tumor. Its clinical management is closely related to the tumor microenvironment (TME). Identifying its potential markers is important for improving prognosis. Therefore, in this study, we successfully constructed a prognostic model of glutathione metabolism–related molecules and screened for GGTLC1 prognostic molecules, while immunohistochemical analysis of the online database HPA and hospital patient specimens showed that GGTLC1 was highly expressed in paracancerous tissues. Taken together, the results of this study suggest that GGTLC1 is a potential prognostic biomarker associated with KIRC. Trial Registration: Chinese Clinical Trial Registry identifier: LSKY: 2022‐112‐01
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: